Skip to main navigation Skip to search Skip to main content

Diagnosis of lung adenocarcinoma in resected specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification

  • William D. Travis
  • , Elisabeth Brambilla
  • , Masayuki Noguchi
  • , Andrew G. Nicholson
  • , Kim Geisinger
  • , Yasushi Yatabe
  • , Yuichi Ishikawa
  • , Ignacio Wistuba
  • , Douglas B. Flieder
  • , Wilbur Franklin
  • , Adi Gazdar
  • , Philip S. Hasleton
  • , Douglas W. Henderson
  • , Keith M. Kerr
  • , Yukio Nakatani
  • , Iver Petersen
  • , Victor Roggli
  • , Erik Thunnissen
  • , Ming Tsao
  • Memorial Sloan-Kettering Cancer Center
  • CHU de Grenoble
  • University of Tsukuba
  • Royal Brompton Hospital
  • Wake Forest University
  • Aichi Cancer Center Hospital and Research Institute
  • Japanese Foundation for Cancer Research
  • University of Texas Health Science Center at Houston
  • University of Colorado Anschutz Medical Campus
  • University of Texas Southwestern Medical Center
  • Wythenshawe Hospital
  • Flinders Medical Centre
  • University of Aberdeen
  • Chiba University
  • Friedrich Schiller University Jena
  • Duke University
  • VU University Medical Center
  • Princess Margaret Cancer Centre

Research output: Contribution to journal › Review article › peer-review

154 Scopus citations

Abstract

A new lung adenocarcinoma classification has been published by the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society. This new classification is needed to provide uniform terminology and diagnostic criteria, most especially for bronchioloalveolar carcinoma. It was developed by an international core panel of experts representing all 3 societies with oncologists/pulmonologists, pathologists, radiologists, molecular biologists, and thoracic surgeons.This summary focuses on the aspects of this classification that address resection specimens. The terms bronchioloalveolar carcinoma and mixed subtype adenocarcinoma are no longer used. For resection specimens, new concepts are introduced, such as adenocarcinoma in situ and minimally invasive adenocarcinoma for small solitary adenocarcinomas with either pure lepidic growth (adenocarcinoma in situ) and predominant lepidic growth with invasion of 5 mm or less (minimally invasive adenocarcinoma), to define the condition of patients who will have 100% or near 100% disease-specific survival, respectively, if they undergo complete lesion resection. Adenocarcinoma in situ and minimally invasive adenocarcinoma are usually nonmucinous, but rarely may be mucinous. Invasive adenocarcinomas are now classified by predominant pattern after using comprehensive histologic subtyping with lepidic (formerly most mixed subtype tumors with nonmucinous bronchioloalveolar carcinoma), acinar, papillary, and solid patterns; micropapillary is added as a new histologic subtype. Variants include invasive mucinous adenocarcinoma (formerly mucinous bronchioloalveolar carcinoma), colloid, fetal, and enteric adenocarcinoma.It is possible that this classification may impact the next revision of the TNM staging classification, with adjustment of the size T factor according to only the invasive component pathologically in adenocarcinomas with lepidic areas.

Original languageEnglish
Pages (from-to)685-705
Number of pages21
JournalArchives of Pathology and Laboratory Medicine
Volume137
Issue number5
DOIs
StatePublished - May 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Diagnosis of lung adenocarcinoma in resected specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European respiratory society classification'. Together they form a unique fingerprint.

Cite this